Listed

Harmony Biosciences Holdings, Inc.

HRMYNasdaqCIK 1802665HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$261.3mRevenue, Q2 FY2026, three months to 2026-06-30$261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 4, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$261.3mRevenue, Q2 FY2026, three months to 2026-06-30$261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure+30.3% on a year earlier
  • Gross margin75.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $198.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure−5.2 pts on a year earlier
  • Operating margin34.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $89.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure+10.2 pts on a year earlier
  • Net margin28.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $75.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure+9.0 pts on a year earlier
  • Diluted EPS$1.28Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure+88.2% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$261.3mGross margin 75.8%
Diluted EPS$1.28, Q2 FY2026
Free cash flow$126.0m, Q4 FY2025
Harmony Biosciences Holdings, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m186Revenue, Q3 FY2024, three months to 2024-09-30$186.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure201Revenue, Q4 FY2024, three months to 2024-12-31$201.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure185Revenue, Q1 FY2025, three months to 2025-03-31$184.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure200Revenue, Q2 FY2025, three months to 2025-06-30$200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure239Revenue, Q3 FY2025, three months to 2025-09-30$239.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure244Revenue, Q4 FY2025, three months to 2025-12-31$243.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure215Revenue, Q1 FY2026, three months to 2026-03-31$215.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure261Revenue, Q2 FY2026, three months to 2026-06-30$261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure
Gross margin%77.0%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $143.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Revenue: $186.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure73.0%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $146.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Revenue: $201.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure82.7%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $152.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Revenue: $184.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure81.0%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $162.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure75.1%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $179.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Revenue: $239.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure71.9%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $175.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Revenue: $243.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure79.3%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $170.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Revenue: $215.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure75.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $198.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure
Operating margin%33.2%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $61.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Revenue: $186.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure27.7%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $55.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Revenue: $201.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure30.4%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $56.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Revenue: $184.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure24.0%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $48.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure27.3%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $65.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Revenue: $239.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure15.8%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $38.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Revenue: $243.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure17.3%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $37.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Revenue: $215.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure34.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $89.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure
Net margin%24.8%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $46.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Revenue: $186.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure24.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $49.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Revenue: $201.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure24.7%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $45.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Revenue: $184.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure19.8%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $39.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure21.2%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $50.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Revenue: $239.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figure9.2%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $22.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Revenue: $243.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure15.1%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $32.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Revenue: $215.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure28.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $75.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Revenue: $261.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure
Diluted EPS$ per share0.79Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figurenot reported (Diluted EPS not reported)0.78Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure0.68Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure0.87Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-105962.Report this figurenot reported (Diluted EPS not reported)0.55Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure1.28Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001104659-26-090090.Report this figure
Free cash flow$m70.5Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $70.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001104659-25-105962. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001104659-25-105962. Derived: 9-month figure less the 6-month figure.Report this figure75.0Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $75.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Capital expenditure: $513.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figure33.9Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $34.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Capital expenditure: $128.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-056720.Report this figure79.3Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $79.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001104659-26-090090. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0001104659-26-090090. Derived: 6-month figure less the 3-month figure.Report this figure109Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $108.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001104659-25-105962. Derived: 9-month figure less the 6-month figure.Capital expenditure: $71.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001104659-25-105962. Derived: 9-month figure less the 6-month figure.Report this figure126Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $126.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Capital expenditure: $107.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018859. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$868.5mGross margin 77.2%
Diluted EPS$2.71, FY2025
Free cash flow$347.9m, FY2025
Harmony Biosciences Holdings, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m305Revenue, FY2021, twelve months to 2021-12-31$305.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001466.Report this figure438Revenue, FY2022, twelve months to 2022-12-31$437.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001558370-25-001441.Report this figure582Revenue, FY2023, twelve months to 2023-12-31$582.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure715Revenue, FY2024, twelve months to 2024-12-31$714.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure868Revenue, FY2025, twelve months to 2025-12-31$868.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure
Gross margin%81.8%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $249.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-22, accession 0001558370-24-001466.Revenue: $305.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001466.Report this figure80.9%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $354.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-25, accession 0001558370-25-001441.Revenue: $437.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001558370-25-001441.Report this figure79.2%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $460.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $582.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure78.1%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $557.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $714.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure77.2%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $670.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $868.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure
Operating margin%28.7%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $87.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-22, accession 0001558370-24-001466.Revenue: $305.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001466.Report this figure27.4%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $120.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-25, accession 0001558370-25-001441.Revenue: $437.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001558370-25-001441.Report this figure33.0%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $192.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $582.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure26.7%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $190.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $714.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure24.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $208.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $868.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure
Net margin%11.3%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $34.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-22, accession 0001558370-24-001466.Revenue: $305.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001466.Report this figure41.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $181.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-25, accession 0001558370-25-001441.Revenue: $437.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0001558370-25-001441.Report this figure22.1%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $128.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $582.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure20.4%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $145.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $714.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure18.3%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $158.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001104659-26-018859.Revenue: $868.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure
Diluted EPS$ per share0.58Diluted EPS, FY2021, twelve months to 2021-12-31$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0001558370-24-001466.Report this figure2.97Diluted EPS, FY2022, twelve months to 2022-12-31$2.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-25, accession 0001558370-25-001441.Report this figure2.13Diluted EPS, FY2023, twelve months to 2023-12-31$2.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure2.51Diluted EPS, FY2024, twelve months to 2024-12-31$2.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure2.71Diluted EPS, FY2025, twelve months to 2025-12-31$2.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure
Free cash flow$m98.3Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $98.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0001558370-24-001466.Capital expenditure: $298.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0001558370-24-001466.Report this figure144Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $144.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-25, accession 0001558370-25-001441.Capital expenditure: $172.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-25, accession 0001558370-25-001441.Report this figure219Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $219.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018859.Capital expenditure: $312.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure219Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $219.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018859.Capital expenditure: $1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure348Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $348.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001104659-26-018859.Capital expenditure: $310.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001104659-26-018859.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Harmony Biosciences Holdings, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$258.6m7,101,965Added+31,930
FMR LLC2026-06-30$130.1m3,574,115Added+416,476
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$104.9m2,880,489Added+166,136
AMERICAN CENTURY COMPANIES INC2026-06-30$92.5m2,539,512Added+434,333
DIMENSIONAL FUND ADVISORS LP2026-06-30$87.1m2,393,588Added+317,078
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$76.6m2,105,053Added+2,738
STATE STREET CORP2026-06-30$67.7m1,859,322Added+74,960
ARMISTICE CAPITAL, LLC2026-06-30$56.9m1,564,000Reduced−60,000
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$52.5m1,442,649Added+119,929
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2026-06-30$47.8m1,312,550Reduced−69,563

Recent filings

All 454 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Harmony Biosciences Holdings, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-3016:15 ET8-K/A5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001104659-26-120673
2026-10-1308:00 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-115282
2026-08-0408:16 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-090090
2026-08-0408:05 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-090086
2026-07-1608:35 ET8-K2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-084095
2026-05-1416:31 ET8-K5.07 Shareholder vote results0001104659-26-061237
2026-05-0709:24 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-056786
2026-05-0708:16 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-056720
2026-04-1408:15 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-042886
2026-04-0308:00 ETDEF 14AProxy statementPeriod 2026-05-140001104659-26-039449

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 24, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1802665
Tickers
HRMY
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:23 ET. Listed shows no prices and gives no investment advice.